Sacituzumab Govitecan (SG; Trodelvy) is a targeted therapy designed for adults with hormone receptor (HR)-positive and human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (MBC) who have received hormone therapy and at least two additional treatments for metastatic disease. It is an antibody-drug conjugate that binds to the Trop-2 antigen, delivering a potent chemotherapy directly to cancer cells6. Clinical trials have demonstrated that SG significantly improves progression-free survival and overall survival compared to traditional chemotherapy in this patient population. This therapy offers a new treatment option for patients with HR+/HER2- MBC, who historically have had limited treatment choices and poor survival outcomes. SG's mechanism of action and clinical efficacy make it a valuable addition to the treatment landscape for this challenging form of breast cancer.

Gilead Sciences Hong Kong Ltd. Taiwan Branch

香港商吉立亞醫藥有限公司台灣分公司

從台灣到全球、從預防到治療
2014年吉立亞醫藥在台灣成立分公司，相信更健康的世界，來自更健康的生命，一路走來與病友同行，從生命到生活，結合科學與創新，與政府單位和社群組織攜手合作，開創生命的健康樣貌。

吉立亞醫藥始終創造第一，在愛滋病毒由預防到治療的旅途上，打造了完整的照顧旅程。在病毒性肝炎上，也推出 C型肝炎全口服抗病毒藥物，更有針對新冠病毒的治療藥物，讓新興傳染病不再是健康的破口。2023年正式跨足癌症治療領域，希望能夠解決更多未被滿足的治療需求。

Creating possible是吉立亞醫藥的信念，更是每個員工的信仰，從台灣到全球，從預防到治療，吉立亞醫藥持續在生命的不可能中，創造更多的可能。